Magic mushroom compound tested as cannabis addiction treatment

NCT ID NCT06660381

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study at Johns Hopkins University is testing whether psilocybin, the active ingredient in magic mushrooms, can help people with cannabis use disorder. Twelve adults will receive two doses of psilocybin along with counseling over 12 weeks. Researchers will track cannabis use and related symptoms for up to 6 months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If this works, it could point toward a new treatment option for cannabis use disorder, helping people reduce or stop their cannabis use.
What could go wrong: This is a very small, early-phase pilot study with only 12 people and no placebo group. The results may not apply to everyone, and psilocybin can cause intense psychological effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANNABIS USE DISORDER

Contacts and locations

Locations

Johns Hopkins Center for Psychedelic and Consciousness Research
RECRUITING

Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.